Stockscreener 앱 받기
29.35
0.86%
0.25
시간 외 거래:
29.06
-0.29
-0.99%
Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference - BioSpace
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing - inkl
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $50 to $78 - Moomoo
Which Is a Better Investment, IDEAYA Biosciences, Inc. or Zymeworks Inc. Stock? - AAII
IDEAYA posts melanoma trial gains, prepares NDA submission - MSN
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data - MarketBeat
Janus Henderson holds 7.27M IDEAYA shares (NASDAQ: IDYA) - Stock Titan
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology - GlobeNewswire
Ideaya Biosciences stock (US45166A1025): Minor price dip amid biotech hiring push - AD HOC NEWS
Precision Trading with Ideaya Biosciences Inc. (IDYA) Risk Zones - Stock Traders Daily
Ideaya Biosciences stock (US45166A1025): Positioned in iShares Genomics ETF holdings - AD HOC NEWS
Time To Worry? Analysts Are Downgrading Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Outlook - Moomoo
Vanguard Group Inc. Buys 97,116 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
Assessing IDEAYA Biosciences (IDYA) Valuation After Positive Darovasertib Phase 2/3 Results And FDA Real-Time Review - Yahoo Finance
Some Analysts Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Estimates - simplywall.st
IDEAYA Biosciences, Inc. (IDYA) reports Q1 loss, misses revenue estimates - MSN
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $53 - Moomoo
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65 - Moomoo
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $53 to $65 - Moomoo
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $50 - Moomoo
IDYA SEC FilingsIdeaya Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Which Is a Better Investment, AnaptysBio, Inc. or IDEAYA Biosciences, Inc. Stock? - AAII
TD Cowen Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating - Moomoo
IDEAYA Biosciences Files New Shelf Registration Statement - TipRanks
IDEAYA Biosciences, Inc. Files Form 8-K SEC Report for May 5, 2026 – Company Information and Common Stock Details - Minichart
Ideaya Biosciences IncEnters Sales Agreement With Jefferies For Common Stock Offering Up To $350 MillionSEC Filing - TradingView
Ideaya Biosciences Inc Files For Mixed Shelf Offering, Size Not Disclosed- SEC Filing - TradingView
IDEAYA (NASDAQ: IDYA) renews shelf, keeps $156.6M ATM capacity - Stock Titan
IDEAYA (NASDAQ: IDYA) has $156.55M ATM capacity remaining under Jefferies sales pact - Stock Titan
IDEAYA (NASDAQ: IDYA) files shelf to sell common stock, debt and warrants - Stock Titan
IDEAYA (NASDAQ: IDYA) reports Q1 loss but holds $972.9M cash - Stock Titan
IDEAYA Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
IDEAYA Biosciences 1Q Loss $98.5M >IDYA - Moomoo
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q1 Revenue $6.6M, vs. FactSet Est of $5.0M - marketscreener.com
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs (PR Newswire) - Aktiellt
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q1 Revenue $6.6M, Vs. FactSet Est of $5.0M - Moomoo
IDYA: Darovasertib met key endpoints in mUM, driving NDA plans and robust pipeline momentum - TradingView
IDEAYA (IDYA) posts Q1 2026 loss, advances darovasertib NDA plan - Stock Titan
IDEAYA says eye cancer drug combo cut progression risk 58% - Stock Titan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now? - Insider Monkey
Technical Reactions to IDYA Trends in Macro Strategies - Stock Traders Daily
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
IDEAYA Biosciences, Inc. $IDYA Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Five new IDEAYA hires receive stock options at $29.10 a share - Stock Titan
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62 - Moomoo
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program - BioSpace
IDEAYA Biosciences to Initiate New Drug Application Submission f - GuruFocus
IDEAYA to file NDA for uveal melanoma drug under FDA fast review - Investing.com Canada
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program – Company AnnouncementFT.com - Financial Times
FDA accepts IDEAYA rare eye cancer drug for real-time review - Stock Titan
Executive pay and auditor vote headline IDEAYA (NASDAQ: IDYA) 2026 meeting - Stock Titan
Mizuho Adjusts Price Target on IDEAYA Biosciences to $52 From $46, Maintains Outperform Rating - marketscreener.com
[ARS] IDEAYA Biosciences, Inc. SEC Filing - Stock Titan
Ideaya Biosciences gets coverage initiation at Barclays and Citizens - MSN
RBC Capital Maintains IDEAYA Biosciences (IDYA) Outperform Recommendation - MSN
0.98%
0.12%
자본화:
|
볼륨(24시간):